Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update

Published on August 5, 2025
MALVERN, Pa.—Ocugen, Inc. (NASDAQ: OCGN), a developer of gene therapies targeting blindness diseases, yesterday reported second quarter 2025 financial results and provided a business update. The company reported revenue of $1.37 million for the three months ended June 30, 2025, compared with $1.41 million in the same period in 2024. Ocugen reported a net loss of $14.7 million for the second quarter of 2025, compared with a net loss of $15.3 million in the prior-year period.
Continue reading on website
Other news

Viridian partners with Kissei Pharmaceutical to advance thyroid eye disease therapies in Japan

August 4, 2025
The partnership marks a major step toward expanding global access to targeted treatments for this vision-threatening condition, according to a news release.

Exploratory analysis discovers key predictive factors of improved BCVA in treatment of LHON disease with lenadogene nolparvovec

August 5, 2025
Better best-corrected visual acuity values and baseline thicker ganglion cell layer and retinal nerve fiber layer at ocular coherence tomography measurements were found to be the key predictive factors.